Expression of heat shock protein 70 in the tissue of patients with laryngeal squamous cell carcinoma

Authors

  • Aleksandra Barańska Chair and Department of Clinical Immunology, Medical University of Lublin, Lublin, Poland https://orcid.org/0000-0001-9949-1134
  • Aleksandra Maziarz Institute of Experimental and Clinical Medicine, Department of Immunology, Faculty of Medicine, University of Rzeszow, Rzeszow, Poland https://orcid.org/0000-0002-1335-1542
  • Jacek Roliński Chair and Department of Clinical Immunology, Medical University of Lublin, Lublin, Poland https://orcid.org/0000-0003-4841-6120
  • Janusz Klatka Chair and Department of Otolaryngology and Laryngological Oncology, II Faculty of Medicine with English Language Division, Medical University of Lublin, Lublin, Poland https://orcid.org/0000-0002-3805-4640
  • Katarzyna Dudzińska-Ćwiek Chair and Department of Otolaryngology and Laryngological Oncology, II Faculty of Medicine with English Language Division, Medical University of Lublin, Lublin, Poland https://orcid.org/0000-0003-4857-2692
  • Jacek Tabarkiewicz Institute of Experimental and Clinical Medicine, Department of Immunology, Faculty of Medicine, University of Rzeszow, Rzeszow, Poland; Centre for Innovative Research in Medical and Natural Sciences, Faculty of Medicine, University of Rzeszow, Rzeszow, Poland https://orcid.org/0000-0002-1264-2882

DOI:

https://doi.org/10.15584/ejcem.2019.1.3

Keywords:

HSP70, LSCC, treatment

Abstract

Introduction. Laryngeal squamous cell carcinoma (LSCC) is a common type of head and neck malignancy. Because of unsatisfactory results of therapy, development of new strategies for LSCC treatment is needed. It is believed that heat shock protein 70 (HSP70) is involved in pathogenesis of LSCC. Thus, targeting HSP70 seems to be promising strategy for laryngeal cancer treatment.

Aim. The aim of the study was to assess the HSP70 concentration in laryngeal squamous cell carcinoma specimens and its correlation with tumor volume and TNM staging.

Material and methods. An ELISA method and a Bradford protein assay were used to evaluate the HSP70 concentration in peripheral blood cells, tumor tissue and lymph nodes from the patients suffering from LSCC.

Results. We demonstrated that the HSP70 concentration is significantly different between examined compartments. The highest level was observed in peripheral blood, while the lowest was in the lymph nodes. The HSP70 expression was correlated to tumor volume.

Conclusion. Our results showed varied expression of HSP70 in tissue from patients with LSCC, but there was no association between HSP70 concentration and TNM staging. Currently, application of HSP70 inhibition as a LSCC treatment could be rather associated with systemic blocking of this molecule than target inhibition in tumor tissue. However, further analysis on a larger group of patients is needed. 

Downloads

Download data is not yet available.

References

Ludwig ML, Birkeland AC, Hoesli R, Swiecicki P, Spector ME, Brenner JC. Changing the paradigm: the potential for targeted therapy in laryngeal squamous cell carcinoma. Cancer Biol Med. 2016;13(1):87-100. doi:10.28092/j.issn.2095-3941.2016.0010

Giotakis AI, Kontos CK, Manolopoulos LD, Sismanis A, Konstadoulakis MM, Scorilas A. High BAX/BCL2 mRNA ratio predicts favorable prognosis in laryngeal squamous cell carcinoma, particularly in patients with negative lymph nodes at the time of diagnosis. Clin Biochem. Clin Biochem. 2016;49(12):890-6. doi:10.1016/j.clinbiochem.2016.04.010

Dempsey NC, Ireland HE, Smith CM, Hoyle CF, Williams JHH. Heat Shock Protein translocation induced by membrane fluidization increases tumor-cell sensitivity to chemotherapeutic drugs. Cancer Letters. 2010;296(2):257-267. doi:10.1016/j.canlet.2010.04.016

Garrido C, Gurbuxani S, Ravagnan L, Kroemer G. Heat Shock Proteins: Endogenous Modulators of Apoptotic Cell Death. Biochemical and Biophysical Research Communications. 2001;286(3):433-442. doi:10.1006/bbrc.2001.5427

Xu J, Wang K, Zhang X, et al. HSP70: a promising target for laryngeal carcinoma radiaotherapy by inhibiting cleavage and degradation of nucleolin. J Exp Clin Cancer Res. 2010;29:106. doi:10.1186/1756-9966-29-106

Weber A, Hengge UR, Stricker I, et al. Protein microarrays for the detection of biomarkers in head and neck squamous cell carcinomas. Hum Pathol. 2007;38(2):228-238. doi:10.1016/j.humpath.2006.07.012

Jäättelä M, Wissing D, Bauer PA, Li GC. Major heat shock protein hsp70 protects tumor cells from tumor necrosis factor cytotoxicity. EMBO J. 1992;11(10):3507-3512.

Bao X-Q, Liu G-T. Heat shock proteins: new target in cytoprotective and tumor therapy. Yao Xue Xue Bao. 2008;43(3):234-240.

Hunt CR, Dix DJ, Sharma GG, et al. Genomic instability and enhanced radiosensitivity in Hsp70.1- and Hsp70.3-deficient mice. Mol Cell Biol. 2004;24(2):899-911.

Kumar S, Stokes J, Singh UP, et al. Targeting Hsp70: A possible therapy for cancer. Cancer Lett. 2016;374(1):156-166. doi:10.1016/j.canlet.2016.01.056

Chen W, Lin K, Zhang L, et al. The cytomegalovirus protein UL138 induces apoptosis of gastric cancer cells by binding to heat shock protein 70. Oncotarget. 2016;7(5):5630-5645. doi:10.18632/oncotarget.6800

Wang X, Shi X, Tong Y, Cao X. The Prognostic Impact of Heat Shock Proteins Expression in Patients with Esophageal Cancer: A Meta-Analysis. Yonsei Med J. 2015;56(6):1497-1502. doi:10.3349/ymj.2015.56.6.1497

Kim LS, Kim JH. Heat Shock Protein as Molecular Targets for Breast Cancer Therapeutics. J Breast Cancer. 2011;14(3):167-174. doi:10.4048/jbc.2011.14.3.167

Gunaldi M, Kocoglu H, Okuturlar Y, et al. Heat shock protein 70 is a useful marker for predicting colorectal cancer. J BUON. 2015;20(6):1464-1470.

Davidson B, Reinertsen KV, Trinh D, Reed W, Bøhler PJ. BAG-1/SODD, HSP70 and HSP90 are potential prognostic markers of poor survival in node-negative breast carcinoma. Hum Pathol. 2016;54:64-73. doi:10.1016/j.humpath.2016.02.023

Calderwood SK. Heat shock proteins in breast cancer progression-a suitable case for treatment? Int J Hyperthermia. 2010;26(7):681-685. doi:10.3109/02656736.2010.490254

Stangl S, Tontcheva N, Sievert W, et al. Heat shock protein 70 and tumor-infiltrating NK cells as prognostic indicators for patients with squamous cell carcinoma of the head and neck after radiochemotherapy: A multicentre retrospective study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG). Int J Cancer. 2018;142(9):1911-1925. doi:10.1002/ijc.31213

Enomoto Y, Bharti A, Khaleque AA, et al. Enhanced Immunogenicity of Heat Shock Protein 70 Peptide Complexes from Dendritic Cell-Tumor Fusion Cells. J Immunol. 2006;177(9):5946-5955. doi:10.4049/jimmunol.177.9.5946

Gong J, Zhu B, Murshid A, et al. T cell activation by HSP70 vaccine requires TLR signaling and scavenger receptor SREC-1. J Immunol. 2009;183(5):3092-3098. doi:10.4049/jimmunol.0901235

Chen T, Guo J, Han C, Yang M, Cao X. Heat shock protein 70, released from heat-stressed tumor cells, initiates antitumor immunity by inducing tumor cell chemokine production and activating dendritic cells via TLR4 pathway. J Immunol. 2009;182(3):1449-1459.

Xu X, Zhao M, Shi Y. Expression of heat shock proteins in laryngeal carcinoma. Zhonghua Er Bi Yan Hou Ke Za Zhi. 1998;33(4):232-234.

Yang S, Chen H, Zhang W, Liu D, Fan E, Li Y. Expression and significance of TGF-beta1 and HSP70 in human laryngeal squamous cell carcinoma. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2007;21(12):531-534.

Malyshev I. HSP70 in the Immune Responses. In: Malyshev I, ed. Immunity, Tumors and Aging: The Role of HSP70. SpringerBriefs in Biochemistry and Molecular Biology. Dordrecht: Springer Netherlands; 2013:63-82. doi:10.1007/978-94-007-5943-5_5

Tavassol F, Starke OF, Kokemüller H, et al. Prognostic significance of heat shock protein 70 (HSP70) in patients with oral cancer. Head Neck Oncol. 2011;3:10. doi:10.1186/1758-3284-3-10

Taghavi N, Mohsenifar Z, Baghban AA, Arjomandkhah A. CD20+ Tumor Infiltrating B Lymphocyte in Oral Squamous Cell Carcinoma: Correlation with Clinicopathologic Characteristics and Heat Shock Protein 70 Expression. Patholog Res Int. 2018;2018:4810751. doi:10.1155/2018/4810751

Luz CCF, Noguti J, de Araújo LB, Santos GMSD, Gomes TS, Neto RA. Hsp27 and Hsp70 Expression in Esophageal Squamous. Asian Pac J Cancer Prev. 2017;18(3):789-794. doi:10.22034/APJCP.2017.18.3.789

Downloads

Published

2019-03-30

How to Cite

Barańska, A., Maziarz, A., Roliński, J., Klatka, J., Dudzińska-Ćwiek, K., & Tabarkiewicz, J. (2019). Expression of heat shock protein 70 in the tissue of patients with laryngeal squamous cell carcinoma. European Journal of Clinical and Experimental Medicine, 17(1), 16–21. https://doi.org/10.15584/ejcem.2019.1.3

Issue

Vol. 17 No. 1 (2019)

Section

ORIGINAL PAPERS

License

Copyright (c) 2019 European Journal of Clinical and Experimental Medicine

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Our open access policy is in accordance with the Budapest Open Access Initiative (BOAI) definition: this means that articles have free availability on the public Internet, permitting any users to read, download, copy, distribute, print, search, or link to the full texts of these articles, crawl them for indexing, pass them as data to software, or use them for any other lawful purpose, without financial, legal, or technical barriers other than those inseparable from having access to the Internet itself.

All articles are published with free open access under the CC-BY Creative Commons attribution license (the current version is CC-BY, version 4.0). If you submit your paper for publication by the Eur J Clin Exp Med, you agree to have the CC-BY license applied to your work. Under this Open Access license, you, as the author, agree that anyone may download and read the paper for free. In addition, the article may be reused and quoted provided that the original published version is cited. This facilitates freedom in re-use and also ensures that Eur J Clin Exp Med content can be mined without barriers for the research needs.